Join
Live feed
·
PRReleasevia Quantisnow
Denali Therapeutics Inc. logo

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

ByQuantisnow·Wall Street's wire, on your screen.
DNLI· Denali Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNLI (Denali Therapeutics Inc.) and more on Quantisnow.